RU2750670C2 - Композиция с задержанным высвобождением, содержащая микронизированный толкапон - Google Patents

Композиция с задержанным высвобождением, содержащая микронизированный толкапон Download PDF

Info

Publication number
RU2750670C2
RU2750670C2 RU2019103647A RU2019103647A RU2750670C2 RU 2750670 C2 RU2750670 C2 RU 2750670C2 RU 2019103647 A RU2019103647 A RU 2019103647A RU 2019103647 A RU2019103647 A RU 2019103647A RU 2750670 C2 RU2750670 C2 RU 2750670C2
Authority
RU
Russia
Prior art keywords
tolcapone
tablet
cellulose
transthyretin
release
Prior art date
Application number
RU2019103647A
Other languages
English (en)
Russian (ru)
Other versions
RU2019103647A (ru
RU2019103647A3 (enExample
Inventor
Анна НАРДИ РИКАРТ
Хосеп Мария Сунье Негре
Нурия РЕЙГ БОЛАНЬО
Рауль ИНСА БОРОНАТ
Оскар УЭРТАС ГАМБИН
Сантьяго ЭСТЕВА ГРАС
Гал.ла Перикот Мор
Original Assignee
Сом Инновейшен Биотех, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сом Инновейшен Биотех, С.Л. filed Critical Сом Инновейшен Биотех, С.Л.
Publication of RU2019103647A publication Critical patent/RU2019103647A/ru
Publication of RU2019103647A3 publication Critical patent/RU2019103647A3/ru
Application granted granted Critical
Publication of RU2750670C2 publication Critical patent/RU2750670C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019103647A 2016-07-29 2017-07-28 Композиция с задержанным высвобождением, содержащая микронизированный толкапон RU2750670C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7 2016-07-29
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (3)

Publication Number Publication Date
RU2019103647A RU2019103647A (ru) 2020-08-28
RU2019103647A3 RU2019103647A3 (enExample) 2020-10-12
RU2750670C2 true RU2750670C2 (ru) 2021-06-30

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019103647A RU2750670C2 (ru) 2016-07-29 2017-07-28 Композиция с задержанным высвобождением, содержащая микронизированный толкапон

Country Status (12)

Country Link
US (2) US11883538B2 (enExample)
EP (2) EP3275433A1 (enExample)
JP (1) JP7047236B2 (enExample)
KR (1) KR102484678B1 (enExample)
CN (1) CN109789100A (enExample)
AU (1) AU2017303333B2 (enExample)
DK (1) DK3490535T3 (enExample)
ES (1) ES2891355T3 (enExample)
MX (1) MX391116B (enExample)
PT (1) PT3490535T (enExample)
RU (1) RU2750670C2 (enExample)
WO (1) WO2018019997A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052504A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
RU2197244C2 (ru) * 1996-05-20 2003-01-27 Джи.Ди.Сирл энд Ко. Фармацевтическая композиция и фармацевтический препарат, содержащие калиевую, натриевую и трис соли оксапрозина, их применение для устранения или уменьшения боли у млекопитающего и для лечения воспаления и нарушений, связанных с воспалением у млекопитающего, способ получения фармацевтического препарата
US20100112053A1 (en) * 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
WO2013060668A1 (en) * 2011-10-24 2013-05-02 Som Innovation Biotech, S.L. New therapy for transthyretin-associated amyloidosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CA2510320C (en) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
EP2335696A1 (en) * 2005-06-08 2011-06-22 Orion Corporation An entacapone-containing oral dosage form
SI2640358T1 (en) * 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
MX355309B (es) 2011-03-14 2018-04-16 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno.
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
CN105209029A (zh) * 2013-03-13 2015-12-30 纽罗德姆有限公司 帕金森病的治疗方法
ES2957768T3 (es) * 2013-11-05 2024-01-25 Synagile Corp Suministro continuo de fármacos a través de la boca
CA3175785A1 (en) * 2014-09-04 2016-03-10 Intrance International Ab Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197244C2 (ru) * 1996-05-20 2003-01-27 Джи.Ди.Сирл энд Ко. Фармацевтическая композиция и фармацевтический препарат, содержащие калиевую, натриевую и трис соли оксапрозина, их применение для устранения или уменьшения боли у млекопитающего и для лечения воспаления и нарушений, связанных с воспалением у млекопитающего, способ получения фармацевтического препарата
WO1999052504A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
US20100112053A1 (en) * 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
WO2013060668A1 (en) * 2011-10-24 2013-05-02 Som Innovation Biotech, S.L. New therapy for transthyretin-associated amyloidosis

Also Published As

Publication number Publication date
RU2019103647A (ru) 2020-08-28
JP7047236B2 (ja) 2022-04-05
KR102484678B1 (ko) 2023-01-03
US20190167596A1 (en) 2019-06-06
MX391116B (es) 2025-03-21
EP3275433A1 (en) 2018-01-31
EP3490535A1 (en) 2019-06-05
KR20190034563A (ko) 2019-04-02
US11883538B2 (en) 2024-01-30
AU2017303333B2 (en) 2023-03-30
JP2019523305A (ja) 2019-08-22
RU2019103647A3 (enExample) 2020-10-12
US20240216282A1 (en) 2024-07-04
EP3490535B1 (en) 2021-07-14
MX2019001190A (es) 2019-09-06
AU2017303333A1 (en) 2019-03-14
PT3490535T (pt) 2021-09-30
CA3032211A1 (en) 2018-02-01
US12220487B2 (en) 2025-02-11
DK3490535T3 (da) 2021-10-04
WO2018019997A1 (en) 2018-02-01
BR112019001826A2 (pt) 2019-05-07
ES2891355T3 (es) 2022-01-27
CN109789100A (zh) 2019-05-21

Similar Documents

Publication Publication Date Title
JP4757872B2 (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
CA2956527C (en) Directly compressible polyvinyl alcohols
AU2014225449B2 (en) Stabilization of moisture-sensitive drugs
US12551486B2 (en) Rivaroxaban formulation
US12220487B2 (en) Sustained release compositions comprising micronized tolcapone
Alshora et al. Optimized flurbiprofen sustained-release matrix pellets prepared by extrusion/spheronization
CA3032211C (en) Sustained release composition comprising micronized tolcapone
WO2006103551A1 (en) Controlled release formulations of oxycodone
JP6002869B1 (ja) ジエノゲスト含有錠剤
HK40008562A (en) Sustained release composition comprising micronized tolcapone
BR112019001826B1 (pt) Composição de liberação prolongada compreendendo tolcapone micronizada
US20240269079A1 (en) Melatonin formulation in solid dosage form
JP2017075138A (ja) ジエノゲスト含有錠剤
WO2021148362A1 (en) Directly compressible polymer combinations for matrix tablets with extended drug release
GB2491205A (en) Composition comprising bosentan and diluents
WO2017064815A1 (ja) 低用量薬物を含有する口腔内崩壊錠